Research programme: cancer therapeutics - Oxis Biotech
Alternative Names: OXS 1950; OXS 2050; OXS 2175; OXS 4550Latest Information Update: 28 May 2019
At a glance
- Originator Oxis Biotech
- Class Bispecific antibodies; Monoclonal antibodies; Small molecules
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell adhesion molecule inhibitors; Cell adhesion molecule modulators; Frizzled 7 receptor antagonists; Frizzled 7 receptor modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Triple negative breast cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (Parenteral, Infusion)
- 28 May 2019 No recent reports of development identified for research development in Cancer in USA
- 12 Apr 2015 Preclinical trials in Triple negative Breast cancer in USA (unspecified route)